The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.

Dermatology Clinical Trials Unit

Stephanie Farris, Clinical Research Coordinator, Main Campus
Phone: 314-747-8694 Fax: 314-362-6080

Mary Tabacchi, CRCC, Sr. Clinical Research Coordinator, All sites
Phone: 314-362-8171 Fax: 314-362-6080

Milan Anadkat, MD, Director, Clinical Trials Unit 

Currently Enrolling Trials

Dr. Milan Anadkat- (COH)

A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981; IL-1 inh) in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Identifier: NCT05139602

A pragmatic study of home versus office-based narrow band ultraviolet B phototherapy for the treatment of psoriasis (Short Title: Light Treatment Effectiveness (LITE) Study) Identifier: NCT03726489

The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy with Clindamycin and Triamcinolone in Glioblastoma Patients Treated with Tumor Treating Fields Identifier: NCT04469075

Phase 2, Placebo-controlled Study of Topically Administered LUT014 (BRAF agonist) in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions Identifier: NCT04759664

Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab (IL-17-inh) in Patients with Active Moderate to Severe Hidradenitis Suppurativa Identifier: NCT05322473

Dr. Amy Musiek- (COH)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 (Deucravacitinib; TYK2 inhibitor) in Subjects with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus Identifier: NCT04857034

A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 (CXCR2 antagonist) in Subjects with Palmoplantar Pustulosis Identifier: NCT05194839

Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis Identifier: NCT03181893

A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms Form of Cutaneous T-Cell Lymphoma (CTCL) Identifier: NCT02811783